Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Saranya Sridhar, Arnel Joaquin, Matthew I. Bonaparte, Agustin Bueso, Anne Laure Chabanon, Aiying Chen, Roman M. Chicz, David Diemert, Brandon J. Essink, Bo Fu, Nicole A. Grunenberg, Helene Janosczyk, Michael C. Keefer, Doris M. Rivera M, Ya Meng, Nelson L. Michael, Sonal S. Munsiff, Onyema Ogbuagu, Vanessa N. Raabe, Randall SeveranceEnrique Rivas, Natalya Romanyak, Nadine G. Rouphael, Lode Schuerman, Lawrence D. Sher, Stephen R. Walsh, Judith White, Dalia von Barbier, Guy de Bruyn, Richard Canter, Marie Helene Grillet, Maryam Keshtkar-Jahromi, Marguerite Koutsoukos, Denise Lopez, Roger Masotti, Sandra Mendoza, Catherine Moreau, Maria Angeles Ceregido, Shelly Ramirez, Ansoyta Said, Fernanda Tavares-Da-Silva, Jiayuan Shi, Tina Tong, John Treanor, Carlos A. Diazgranados, Stephen Savarino
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study'. Together they form a unique fingerprint.